1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Peijia Medical Ltd.

Peijia Medical Ltd.

0.47
EUR
-0.02
(-4.44%)
432.02MMarket Cap
Apr 01Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.03
0.08
0.21
0.37
0.65
0.92
1.07
- -
Basic EPS, GAAP
-0.14
-0.87
-4.43
-0.87
-0.61
-0.58
-0.34
-0.31
- -
Free Cash Flow per Basic Share
-0.08
-0.19
-0.45
-0.96
-0.86
-1.39
-0.43
-0.49
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.15
-0.92
4.44
4.53
3.92
3.37
3.05
2.75
2.75
Tangible Book Value per Share
-0.16
-1.28
4.08
4.01
3.1
2.52
2
1.6
1.6
Basic Weighted Avg Shares
610
610
467
662
673
679
669
665
668
Sales/Revenue/Turnover
- -
19
39
137
251
441
615
713
- -
Operating Margin (%)
- -
-1,189.21
-541.37
-402.54
-219.96
-94.27
-37.42
-27.4
- -
Depreciation Expense
5
13
19
27
36
43
59
68
- -
Net Income, GAAP
-83
-532
-2,069
-574
-408
-393
-227
-203
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-2,844.95
-5,351.59
-420.57
-162.58
-88.98
-36.81
-28.52
- -
Working Capital
96
507
2,500
2,308
1,429
1,083
544
143
143
LT Debt
1
1
- -
4
73
205
162
41
41
Total Equity
-94
-558
2,813
3,019
2,638
2,274
2,045
1,858
1,858
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-19.69
-14.42
-15.98
-10.53
-10.5
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
92
227
393
LT Borrowings
158
91
38
LT Finance Leases
3
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
665
667
670
Market Capitalization
2,477
3,799
3,549

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
987
827
822
Cash, Cash Equivalents & STI
713
602
550
Accounts Receivable, Net
101
59
46
Inventories
141
137
146
Total Current Liabilities
443
463
679
Payables & Accruals
- -
- -
- -
ST Debt
92
227
393
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.66%
-9.12%
Free Cash Flow
- -
40.73%
14.02%
Net Income, GAAP
- -
-31.51%
-10.28%
Sales/Revenue/Turnover
- -
93.63%
15.82%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
441
2024
- -
- -
615
2025
- -
- -
713

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.58
2024
- -
- -
-0.34
2025
- -
- -
-0.31

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yi Zhang
Full Time Employees
1,022
Sector
Health technology
Industry
Medical specialties
Address
No.18 Yangjiatian Road Suzhou JS China 215028
IPO Date
May 15, 2020
Website
peijiamedical.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Peijia Medical Limited (9996.HK) is a leading Chinese developer, manufacturer and seller of interventional medical devices for structural heart and neurovascular diseases. Founded in 2012 and headquartered in Suzhou, Jiangsu Province, China, the company operates primarily in China with manufacturing facilities in Suzhou and Shanghai, and pursues global expansion through strategic partnerships and clinical trials. It focuses on high-growth segments including transcatheter valve therapeutics and neurointerventional procedural solutions; core products encompass transcatheter aortic valve replacement (TAVR) systems such as TaurusOne, TaurusElite, TaurusMax and crosslinked dry-tissue/polymeric tri-leaflet variants; mitral and tricuspid valve devices including GeminiOne transcatheter edge-to-edge repair (TEER) and HighLife transseptal mitral valve replacement (TSMVR); neurointerventional devices comprising hemorrhagic products like flow-diverting stents (YonFlow), balloon dilatation catheters (SacSpeed, Fastunnel), coils; ischemic products including DCwire micro guidewires; and access devices; the company also offers procedural solutions for aortic regurgitation (AR), stenosis (AS) and next-generation technologies such as robotic-assisted TAVR (ReachTactile) and lithotripsy valvuloplasty. In recent developments, Peijia Medical announced 2025 interim results showing revenue of RMB353.4 million, up 17.3% year-over-year, with TAVR products up 24% and neurointerventional up 12.2%; its transcatheter valve therapeutic business achieved first-ever commercial profit of RMB29.1 million; the NMPA approved YonFlow flow-diverting stent in April 2025 with first commercial implant in June 2025 and listings in over 20 provinces; pivotal trials advanced for TaurusTrio AR TAVR (registration accepted April 2025), TaurusNXT durability-enhanced AS TAVR and GeminiOne mitral TEER (registrations pending late 2025-mid 2026); DCwire micro guidewire filed for U.S. FDA 510(k) in July 2025; the company entered a strategic innovation partnership with dsm-firmenich in 2025 for polymer heart valve materials including ultra-high molecular weight polyethylene and thermoplastic polyurethane; and it expanded hospital coverage to over 720 institutions with TAVR implant volume exceeding 2,050 units in H1 2025.

Company News

Company News APIChatGPT

  • prnewswire.com

    Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System